title: The perils of clinical trials.
abstract: When the maximal reabsorptive capacity for glucose is lowered by blockade of the activity of sodium-glucose cotransporter-2 (SGLT2), glucosuria occurs in proportion to the plasma glucose and glomerular filtration rate. Accordingly, the modest, 0.44%, hemoglobin A1c reduction found by Kohan et al. in diabetic patients with relatively good glycemic control and chronic kidney disease stage 3 treated with an SGLT2 inhibitor might have been anticipated. The 0.32% fall in hemoglobin A1c in the placebo group, however, seems less expected.
authors.affiliation: Department of Medicine, University of Toronto, St Michael's Hospital, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Gilbert
mesh_terms: D001559:Benzhydryl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000097:blood*; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; C529054:dapagliflozin